Overview

Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases, with most patients dying from respiratory failure 3-5 years after the onset. The purpose of this study is to explore the efficacy and safety of nerve growth factor (NGF) encapsulated with 2-methacryloyloxyethyl phosphorylcholine (MPC) nanocapsules in the treatment of ALS patients.

Phase:

PHASE2

Details

Lead Sponsor:

Beijing Tiantan Hospital

Collaborators:

Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation
Beijing University of Chemical Technology

Treatments:

Nerve Growth Factor